Adaptogen Regulatory Status And FDA Classification

A comprehensive regulatory science guide for consumers, formulators, and health professionals

---

Table of Contents

1. What Is an Adaptogen? Defining a Term the FDA Does Not Recognize
2. The Core Regulatory Reality: Adaptogen FDA Classification Does Not Exist
3. How the FDA Actually Classifies Adaptogen Products
4. Adaptogen Supplement Regulation Under DSHEA
5. New Dietary Ingredient Notifications: Does Your Adaptogen Need One?
6. Adaptogen GRAS Status: What It Means and What It Does Not
7. KSM-66 GRAS and the Ashwagandha Regulatory Pathway
8. Ashwagandha FDA Considerations: Specific Regulatory Spotlight
9. Permissible Claims vs. Drug Claims: The Line Every Marketer Must Understand
10. Structure/Function Claims for Adaptogen Products: Rules and Examples
11. FTC Substantiation Requirements for Adaptogen Advertising
12. Cosmetic Adaptogens: A Separate and Distinct Regulatory Lane
13. Recent Clinical Research (2024–2026): What the Science Is Building
14. Are Adaptogens Legal? The Adaptogen Legal Framework Summarized
15. Third-Party Certifications: USP, NSF, and What They Actually Mean
16. Safety, Drug Interactions, and Consumer Due Diligence
17. Key Takeaways for Industry Professionals and Consumers
18. Frequently Asked Questions

---

Introduction

The word "adaptogen" appears on thousands of supplement bottles, wellness apps, functional beverage labels, and social media posts every single day. It conjures images of ancient Ayurvedic herbs, Siberian tundra roots, and traditional Chinese medicinal mushrooms, all working together to help the human body resist stress, fatigue, and the wear of modern life.

But here is the question that almost nobody stops to ask: What does the United States Food and Drug Administration actually think of the word "adaptogen"?

The answer, as you will discover in this guide, is both simpler and more complicated than most people expect. The FDA does not recognize "adaptogen" as a formal regulatory category. There is no FDA adaptogen approval process, no adaptogen-specific monograph, and no official definition that distinguishes an adaptogenic herb from any other botanical ingredient sold in the American marketplace. What governs these products instead is a layered, use-dependent regulatory framework that routes products into different legal categories — dietary supplement, food, cosmetic, or drug — based primarily on what a manufacturer claims the product does.

Understanding that framework is not just a matter of regulatory compliance. It is a matter of consumer safety, honest marketing, and scientific integrity. This post examines every layer of that framework with specificity, drawing on current FDA guidance, the Dietary Supplement Health and Education Act (DSHEA), recent clinical research from 2024 through 2026, and the landmark ingredient-specific GRAS determinations that have shaped the market in recent years.

Whether you are a supplement brand trying to understand your label obligations, a clinician recommending adaptogens to patients, or a consumer trying to figure out what FDA approval really means when it appears — or pointedly does not appear — on a product's label, this guide is written for you.

---

---

What Is an Adaptogen? Defining a Term the FDA Does Not Recognize

Before addressing regulatory status, it is worth establishing what the term "adaptogen" actually means from a scientific and historical perspective, because the definitional gap between the scientific community and federal regulators is itself one of the most important regulatory facts in this space.

The Scientific Origin of the Term

The term "adaptogen" was coined in 1947 by Soviet pharmacologist Nikolai Lazarev, who used it to describe substances that could increase the body's "nonspecific resistance" to stress. His colleague Israel Brekhman later popularized the concept through extensive research on Eleutherococcus senticosus (Siberian ginseng) and established what became the classic three-criterion definition of an adaptogen:

1. The substance must be nontoxic to the recipient at normal doses.
2. The substance must produce a nonspecific physiological response that increases resistance to multiple stressors.
3. The substance must normalize body functions regardless of the direction of pathological change.

Modern researchers and practitioners have continued to refine this definition. Today, the term is often applied to plants and fungi whose primary bioactive compounds — including ginsenosides in Panax ginseng, withanolides in ashwagandha, rosavins in rhodiola, and beta-glucans in medicinal mushrooms — appear to modulate the hypothalamic-pituitary-adrenal (HPA) axis and the stress response system.

The Regulatory Gap

Despite this relatively well-developed scientific concept, the FDA has not adopted the term "adaptogen" into its regulatory vocabulary. There is no CFR section that defines an adaptogen. There is no FDA guidance document that draws regulatory distinctions between adaptogens and other botanicals. There is no premarket approval pathway labeled "adaptogen approval."

This absence is not an oversight. It reflects a fundamental characteristic of U.S. dietary supplement law: the regulatory category a product occupies is determined not by what the product is, but by what claims are made about it and how it is formulated and marketed. A botanical can be the same plant whether it is sold in a tea bag, a capsule, or a dermatological serum — but each of those formats may be regulated entirely differently.

Understanding this use-based classification system is the foundation of everything else covered in this guide.

---

The Core Regulatory Reality: Adaptogen FDA Classification Does Not Exist

Let us be direct about the most important fact in this entire article: the FDA does not recognize "adaptogen" as a formal regulatory category.

This is not a fringe interpretation or a gray area. It is the regulatory consensus confirmed by multiple federal sources, industry legal experts, and academic analysts. Products marketed as adaptogens do not belong to a special FDA-recognized class. They do not have a dedicated approval pathway. They are not reviewed under a unique set of safety standards.

What the FDA Does Recognize

The FDA operates under a statutory framework established by the Federal Food, Drug, and Cosmetic Act (FD&C Act) and its amendments, including DSHEA (1994). Under this framework, the primary categories relevant to adaptogen products are:

• Conventional Foods — Regulated primarily for safety and accurate labeling. Subject to food additive approval or GRAS standards.
• Dietary Supplements — Regulated under DSHEA. Not subject to premarket approval. Manufacturers responsible for safety and accurate labeling.
• Drugs (Prescription and OTC) — Subject to rigorous premarket approval via New Drug Application (NDA) or Abbreviated New Drug Application (ANDA). Drug claims trigger drug regulatory status.
• Cosmetics — Subject to safety and labeling requirements under the FD&C Act and the Modernization of Cosmetics Regulation Act of 2022 (MoCRA). Not subject to premarket approval but subject to safety documentation requirements.
• Biologics — Regulated by FDA's Center for Biologics Evaluation and Research (CBER). Not typically relevant to botanical adaptogens.

An adaptogen product will fall into one of the first four categories — or potentially more than one simultaneously, which creates its own complications — based on how it is formulated, labeled, marketed, and sold.

The Consequence of Misunderstanding This

When a consumer sees a bottle of ashwagandha extract and assumes it has been "FDA approved," they are operating under a misunderstanding with real consequences. The product has not been reviewed for efficacy. It has not been evaluated for safety by federal scientists before reaching store shelves. The FDA's role is primarily post-market: investigating complaints, issuing warning letters, and taking enforcement action when products violate the law.

This does not mean adaptogen supplements are unsafe or that their manufacturers are cutting corners. Many high-quality adaptogen products exist, backed by substantial research. But the regulatory framework governing them is fundamentally different from the framework governing prescription drugs or vaccines, and that difference matters enormously.

---

How the FDA Actually Classifies Adaptogen Products

As established above, classification depends on intended use. The FDA's 2024 guidance on complementary and alternative medicine products explicitly reaffirms this principle: botanical and functional-food products may be regulated as foods, dietary supplements, or drugs based largely on intended use and statutory classification.

Here is how the classification logic typically flows for an adaptogen product.

Step One: What Is the Product's Intended Use?

The FDA determines intended use by examining:

• Label claims — What does the label say the product does?
• Labeling and accompanying materials — What does the website, promotional material, or insert say?
• Marketing and advertising — What do the company's social media channels, influencer partnerships, and advertising campaigns communicate?
• The product's history of use — Has it been marketed previously in a way that establishes an intended use?

If the label says the product "supports healthy stress response," that is likely a structure/function claim appropriate for a dietary supplement. If the label says the product "treats chronic anxiety disorder," that is a drug claim, and the product is now an unapproved drug regardless of what it is physically made of.

Step Two: Does the Formulation Fit a Recognized Category?

A capsule or tablet containing dried herb powder or standardized plant extract is the format most clearly associated with dietary supplements. A beverage with added botanical extracts may be a dietary supplement or a food depending on how it is represented. A cream or serum containing botanical adaptogens is likely a cosmetic. A product specifically formulated to treat a disease condition is likely a drug.

Step Three: Is the Ingredient Already in the Food Supply?

For foods and dietary supplements, a critical question is whether an ingredient was marketed as a dietary supplement or food before October 15, 1994 (the date DSHEA was enacted). Ingredients marketed after that date may require a New Dietary Ingredient (NDI) notification, discussed in detail below.

The Multi-Category Problem

One of the most practically challenging aspects of adaptogen regulation in the US is that the same botanical ingredient might simultaneously occupy different regulatory categories in different product formats. Ginseng extract in a capsule is a dietary supplement. The same ginseng extract in a therapeutic cream claiming to treat eczema is a drug. Ginseng tea in a grocery store is a food. The ingredient has not changed. The regulatory category has.

This means that supplement regulation for adaptogens is not a single set of rules — it is an interlocking web of rules that applies differently depending on what you put the ingredient in and what you say about it.

---

Adaptogen Supplement Regulation Under DSHEA

The Dietary Supplement Health and Education Act of 1994 (DSHEA) is the foundational statute governing the vast majority of products sold as adaptogens in the United States. Understanding DSHEA is essential to understanding adaptogen regulation in the US.

What DSHEA Does

DSHEA created a distinct regulatory category for "dietary supplements" that is separate from both food and drugs. Under DSHEA:

• Dietary supplements are defined as products intended to supplement the diet that contain one or more of the following: vitamins, minerals, herbs or other botanicals, amino acids, dietary substances to supplement the diet by increasing total dietary intake, or concentrates, metabolites, constituents, extracts, or combinations of these substances.
• Manufacturers are not required to prove safety or efficacy before marketing a dietary supplement, with exceptions for new dietary ingredients (NDIs).
• Manufacturers are responsible for ensuring their products are safe and that their labeling is truthful and not misleading.
• The FDA bears the burden of proving that a supplement is unsafe after it reaches the market — an important distinction from the drug approval framework.

What DSHEA Does Not Do

DSHEA does not:

• Grant FDA approval to any dietary supplement.
• Establish that any supplement is effective.
• Require clinical trials before marketing.
• Create a special "adaptogen" category within dietary supplement regulation.
• Prevent the FDA from taking enforcement action against unsafe or mislabeled products.

Supplement FDA Classification: The Practical Reality

Under adaptogen supplement regulation, a company can bring ashwagandha, rhodiola, schisandra, or lion's mane mushroom to market in capsule form without seeking FDA permission — provided the ingredient is not a new dietary ingredient (as defined under DSHEA), the product does not make drug claims, and the manufacturer has a reasonable basis for believing the product is safe.

This structure places significant responsibility on manufacturers and significant trust in the market. It also creates the conditions for consumer confusion, because the phrase "not FDA approved" on a supplement label looks different from "not FDA approved" on an unapproved drug — but both are technically accurate statements that communicate very different things about the product's risk profile.

---

New Dietary Ingredient Notifications: Does Your Adaptogen Need One?

One of the most practically significant — and most often misunderstood — aspects of adaptogen supplement regulation is the New Dietary Ingredient (NDI) notification requirement.

The Legal Framework

Under DSHEA Section 8, a dietary supplement that contains a "new dietary ingredient" — meaning an ingredient not marketed in the United States as a dietary supplement before October 15, 1994 — is deemed adulterated unless the manufacturer submits a premarket notification to the FDA at least 75 days before marketing.

That notification must include:

• The name of the new dietary ingredient.
• A description of the conditions of use.
• The basis on which the manufacturer concludes the ingredient is reasonably expected to be safe under those conditions of use, including, where possible, information about the history of use or other evidence of safety.

This is not an approval process. The FDA reviews the notification and may respond with questions or objections, but the absence of an FDA objection does not constitute approval. It means the manufacturer submitted a notification and the FDA did not formally object within the review window.

Which Adaptogens Are "New"?

This is where the regulatory picture becomes complicated. Many of the most popular adaptogenic herbs — ashwagandha, ginseng, eleuthero, rhodiola, schisandra, holy basil — have histories of use as foods or dietary supplements that predate 1994, and therefore may not require NDI notifications. However, novel extracts, standardized concentrates, or significantly modified forms of even traditional herbs may qualify as new dietary ingredients requiring notification.

The FDA has taken the position that significant changes in how an ingredient is processed, concentrated, or combined can create a new dietary ingredient even when the base botanical has a pre-1994 marketing history. This means that a proprietary ashwagandha extract standardized to an unusually high concentration of withanolides might require an NDI notification even though plain ashwagandha root powder does not.

For brands building adaptogen formulations with novel proprietary extracts, this is a critical regulatory consideration that requires careful legal and regulatory review.

---

Adaptogen GRAS Status: What It Means and What It Does Not

The term "GRAS" — Generally Recognized as Safe — comes up frequently in discussions of adaptogen regulation US, particularly in the context of adaptogens used in food and beverage applications. Understanding what GRAS means, and crucially what it does not mean, is essential.

What Is GRAS?

Under the FD&C Act, a substance added to food must either be an approved food additive (subject to a formal premarket approval process) or be Generally Recognized as Safe. A substance qualifies as GRAS when:

• Its use is generally recognized by qualified scientific experts as safe, and
• The recognition of safety is based on scientific evidence that is widely available (either published in peer-reviewed journals or otherwise publicly available), or
• The substance has an established history of safe use in food prior to 1958.

The Self-GRAS Problem

Beginning in the 1990s, the FDA established a voluntary GRAS notification program that allows companies to notify the FDA of their determination that a substance is GRAS. Critically, the FDA does not "approve" or "deny" GRAS status through this program. It issues one of three responses: a "no questions" letter indicating the FDA has no questions about the notification, a letter noting the notification was withdrawn, or cessation of evaluation.

A "no questions" letter is frequently misinterpreted as FDA approval of safety. It is not. It indicates that the FDA reviewed the notification and had no questions about the basis for the GRAS determination — a meaningful but distinct regulatory status from an approved food additive.

Adaptogen GRAS in Practice

Several adaptogenic ingredients have received GRAS determinations — either through the FDA's voluntary notification program or through self-affirmation GRAS assessments conducted by companies and their expert panels. These determinations are significant for manufacturers who want to incorporate adaptogen ingredients into conventional food and beverage products rather than dietary supplements.

An ingredient with GRAS status for food use can be added to functional foods, beverages, and similar products without requiring food additive approval. An ingredient that is only GRAS for supplement use, or that lacks any GRAS determination, may not lawfully be added to conventional foods.

---

KSM-66 GRAS and the Ashwagandha Regulatory Pathway

No discussion of adaptogen GRAS status would be complete without addressing the most commercially significant example: KSM-66 ashwagandha and its GRAS determination.

What Is KSM-66?

KSM-66 is a branded, full-spectrum ashwagandha root extract developed by Ixoreal Biomed. It is standardized to contain at least 5% withanolides and is produced using a milk-based extraction process designed to preserve the full spectrum of bioactive compounds present in the ashwagandha root. It is one of the most widely studied and commercially used ashwagandha extracts in the global supplement market.

KSM-66 GRAS Status

KSM-66 received a "no questions" response from the FDA through the GRAS notification program, making KSM-66 GRAS one of the first concrete examples of the FDA engaging formally with an adaptogenic ingredient's safety documentation in a food context.

This KSM-66 GRAS determination means that:

• KSM-66 ashwagandha extract can be used as an ingredient in conventional food and beverage products (subject to specified use conditions).
• Manufacturers using KSM-66 in food products have a defined regulatory basis for its use that goes beyond the standard dietary supplement framework.
• The determination was based on a substantial body of toxicological and clinical evidence reviewed by a panel of qualified scientific experts.

What KSM-66 GRAS Does Not Mean

It does not mean that:

• KSM-66 has been approved by the FDA as a drug.
• Products containing KSM-66 can make drug claims.
• The FDA has evaluated the efficacy of KSM-66 for stress, anxiety, sleep, or any other condition.
• Other ashwagandha extracts (even chemically similar ones) automatically carry the same regulatory status.

The KSM-66 GRAS pathway is an excellent model for how adaptogen regulatory science can advance through rigorous documentation, even within a framework that stops well short of drug approval.

---

---

Ashwagandha FDA Considerations: Specific Regulatory Spotlight

Ashwagandha (Withania somnifera) is arguably the most commercially dominant adaptogen in the American market. It is also the adaptogen that has attracted the most specific FDA regulatory attention, making ashwagandha FDA considerations worthy of their own dedicated section.

Ashwagandha as a Dietary Supplement

The vast majority of ashwagandha products in the United States are sold as dietary supplements. Under the supplement regulation framework established by DSHEA, these products do not require premarket FDA approval. Manufacturers can market ashwagandha capsules, powders, and liquid extracts without submitting safety data to the FDA, provided the ingredient is not a new dietary ingredient and the product does not make drug claims.

Ashwagandha root and root extract have documented pre-1994 marketing histories in the United States, which generally means that standard ashwagandha preparations do not require NDI notifications. However, as noted above, novel extraction methods, unusual standardization levels, or significantly concentrated forms may require NDI submissions even for this traditional ingredient.

The Drug Claim Danger Zone

Where companies run into FDA regulatory trouble with ashwagandha is claims. The following types of claims have historically drawn FDA warning letters or are at high risk of triggering drug-claim enforcement:

• "Treats anxiety disorder"
• "Reduces cortisol levels" (when stated as a disease/disorder treatment rather than a structure/function claim)
• "Treats adrenal fatigue"
• "Cures insomnia"
• "Treats hypothyroidism" (a particular concern given ashwagandha's potential thyroid effects)
• "Treats hormonal imbalance"

By contrast, the following types of claims are typically acceptable as structure/function claims:

• "Helps the body adapt to occasional stress"
• "Supports a healthy stress response"
• "Promotes relaxation"
• "Supports healthy energy levels"

The line between these categories is not always obvious, and it is drawn by FDA enforcement history as much as by statute. Companies operating in the ashwagandha space need regulatory counsel familiar with both DSHEA and FDA warning letter precedent.

Ashwagandha Safety Signals

In 2023–2024, the European Food Safety Authority (EFSA) and regulatory bodies in several EU member states raised safety signals about ashwagandha, particularly regarding potential hepatotoxicity (liver toxicity) from high-dose or long-term use. While the FDA has not issued a formal warning about ashwagandha at the time of this writing, these international signals are relevant to the US market for several reasons:

1. FDA post-market surveillance may increase based on international safety signals.
2. Manufacturers with GRAS determinations or robust safety documentation are better positioned to respond to regulatory scrutiny.
3. Consumers and clinicians should be aware that "dietary supplement" status does not mean proven safety in all populations at all doses.

---

Permissible Claims vs. Drug Claims: The Line Every Marketer Must Understand

One of the most practically important aspects of adaptogen regulation in the US is the distinction between permissible dietary supplement claims and drug claims. This distinction determines whether a product can be marketed legally as a dietary supplement or becomes, in the eyes of the law, an unapproved drug.

The Three-Category Claim Framework

Under DSHEA and FDA regulations, dietary supplement labels may contain three types of claims:

1. Nutrient Content Claims These describe the level of a nutrient in a product (e.g., "high in vitamin C"). They are less relevant to adaptogens but may apply in specific formulations.

2. Health Claims These link a nutrient or ingredient to a disease or health-related condition. Health claims must be authorized by the FDA through a formal petition process or be backed by significant scientific agreement. Very few, if any, adaptogen ingredients have been the subject of authorized health claims.

3. Structure/Function Claims These describe how an ingredient maintains or affects normal structure or function in the body. They do not require FDA authorization but must be truthful, substantiated, and accompanied by the required disclaimer. This is the primary category available for adaptogen supplement claims.

Disease Claims: The Bright Line

A disease claim is a statement that a product diagnoses, cures, mitigates, treats, or prevents a disease. Under the FD&C Act, a product that makes disease claims is a drug, period — regardless of its physical composition, how it is packaged, or whether it is sold in the supplement aisle.

For adaptogens, common disease-claim mistakes include:

| Impermissible Disease Claim | Why It's a Problem | |---|---| | "Treats chronic stress disorder" | Chronic stress disorder is a disease; treating it is a drug claim | | "Reduces cortisol in adrenal fatigue" | "Adrenal fatigue" is a diagnosed condition in context | | "Cures insomnia" | Insomnia is a disease; curing it is a drug claim | | "Balances hormones in PCOS" | PCOS is a disease; hormonal treatment is a drug claim | | "Supports immune function in cancer patients" | Disease-context claim |

The Required Disclaimer

When a dietary supplement makes a structure/function claim, the label must include the following disclaimer in a prominent location, in a box, separated from other text:

"These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease."

This disclaimer is not a loophole and it is not a shield against FDA enforcement. It is a required disclosure that informs consumers the claim has not been FDA-evaluated. If the underlying claim is actually a disease claim, the disclaimer does not save the product from regulatory action.

---

Structure/Function Claims for Adaptogen Products: Rules and Examples

Understanding structure/function claims in more detail is essential for anyone formulating or marketing adaptogen supplement products, because this is the primary — and in most cases only — avenue for making meaningful claims about what adaptogens do.

Legal Requirements for Structure/Function Claims

Under 21 CFR Part 101.93, a dietary supplement manufacturer making a structure/function claim must:

1. Substantiate the claim: Have competent and reliable scientific evidence supporting the claim before making it. This does not require FDA premarket review, but it does require a documented evidence base.
2. Notify the FDA: Submit a notification to FDA within 30 days of first marketing a product with a structure/function claim.
3. Include the disclaimer: Display the required four-part disclaimer prominently on the label.
4. Avoid disease claims: Ensure the claim does not explicitly or implicitly reference a disease.

Substantiation Standard

The FDA's substantiation standard for structure/function claims requires "competent and reliable scientific evidence." This is a flexible standard that considers the quality, quantity, and relevance of available evidence. While the FDA does not prescribe a specific number of clinical trials, the agency and the FTC (which applies a similar standard to advertising claims) have generally indicated that well-designed human clinical trials are the gold standard of substantiation.

For adaptogen claims, this means that a company claiming its ashwagandha product "supports a healthy stress response" should ideally have:

• Human clinical trials demonstrating statistically significant effects on validated stress measures.
• Preferably randomized, double-blind, placebo-controlled trial designs.
• Adequate sample sizes for the claimed effect.
• Published, peer-reviewed results.

Examples of Acceptable Structure/Function Claims for Adaptogens

• "Helps the body adapt to physical and mental stress"
• "Supports healthy cortisol levels already within normal range"
• "Promotes a balanced stress response"
• "Supports mental clarity during times of stress"
• "Promotes healthy energy and stamina"
• "Supports immune system function"
• "Promotes restful sleep"
• "Supports mood and emotional balance"

Notice the language patterns: "supports," "promotes," "helps maintain," "during times of." These constructions signal normal physiological support rather than disease treatment.

---

FTC Substantiation Requirements for Adaptogen Advertising

While the FDA governs product labeling and classification, the Federal Trade Commission (FTC) governs advertising claims for dietary supplements, including adaptogen products. The two agencies operate under a memorandum of understanding that coordinates their enforcement activities, and both apply substantiation standards that supplement marketers must meet.

The FTC's Standard

The FTC requires that advertising claims be truthful, not misleading, and substantiated by "competent and reliable scientific evidence" — a standard the FTC has specifically defined to mean:

Tests, analyses, research, studies, or other evidence based on the expertise of professionals in the relevant area, that has been conducted and evaluated in an objective manner by persons qualified to do so, using procedures generally accepted in the profession to yield accurate and reliable results.

In practice, for health claims about adaptogens, this standard typically requires randomized controlled trials. The FTC has been increasingly aggressive about the quality of evidence it expects, particularly for claims about specific health outcomes like reduced stress, improved sleep, or enhanced cognitive performance.

FTC Enforcement in the Supplement Space

The FTC has brought numerous enforcement actions against supplement companies for unsubstantiated health claims, including cases involving stress, cognitive function, and immune support — all claim categories relevant to adaptogens. Penalties have included substantial monetary settlements, injunctions against specific claims, and mandatory corrective advertising.

For adaptogen brands, the takeaway is clear: the claim substantiation requirement is not a technicality. Both the FDA and the FTC expect real scientific evidence, and both agencies actively monitor the market for violations. Adaptogen supplement regulation in the US involves not just one federal agency but two.

---

Cosmetic Adaptogens: A Separate and Distinct Regulatory Lane

Not all adaptogen products are consumed orally. The cosmetics industry has developed a significant and growing category of topically applied products featuring adaptogenic botanical ingredients — serums, creams, toners, and masks featuring ashwagandha, reishi, schisandra, ginseng, rhodiola, and more.

These products occupy a fundamentally different regulatory lane from dietary supplements, and understanding that distinction matters both for manufacturers and consumers.

Cosmetics vs. Drugs: The Intended Use Test Again

Under the FD&C Act, a cosmetic is defined as an article intended to be rubbed, poured, sprinkled, sprayed on, introduced into, or otherwise applied to the human body for cleansing, beautifying, promoting attractiveness, or altering appearance. A drug is an article intended to diagnose, cure, mitigate, treat, or prevent disease, or to affect the structure or function of the body.

The critical implication: a topical product with adaptogens can make cosmetic claims freely. A topical product with adaptogens that makes drug-type claims about affecting the structure or function of the skin may be regulated as a drug — which means it could be an unapproved drug if it has not gone through FDA's drug approval process.

This is not hypothetical. Many cosmetic companies have received FDA warning letters because their marketing for skincare products crossed the line from cosmetic claims ("reduces the appearance of fine lines") to drug claims ("treats photoaged skin").

The Modernization of Cosmetics Regulation Act (MoCRA)

The cosmetic regulatory landscape in the US changed significantly with the passage of MoCRA in December 2022, which became effective in phases through 2024. MoCRA introduced new requirements for cosmetic manufacturers, including:

• Facility registration with the FDA.
• Product listing for cosmetic products.
• Adverse event reporting requirements.
• Serious adverse event recordkeeping.
• Safety substantiation requirements for cosmetic products.

For adaptogen cosmetic products, MoCRA represents a significant tightening of the regulatory environment. Companies that previously operated with minimal FDA interaction now have affirmative obligations — registration, listing, and safety documentation — that must be met.

Recent 2026 Cosmetic Adaptogen Research

A noteworthy 2026 multicenter clinical study evaluated a topical serum containing 13 plant-based adaptogens in women aged 46 and older experiencing perimenopausal or postmenopausal skin changes. The 16-week, open-label study reported statistically significant improvements (at p < 0.0001) across multiple skin parameters: elastosis, wrinkles, hydration, transepidermal water loss, erythema, texture, pore size, and pigmentation. Adverse events were mild, and no participants discontinued due to adverse events.

This study is significant for several reasons. First, it demonstrates the growing scientific rigor being applied to adaptogen topical applications. Second, the multi-outcome improvements across diverse skin parameters — with statistical significance at p < 0.0001 — provide the kind of evidence that substantiates cosmetic structure/function claims about skin appearance and barrier function. Third, the menopausal population focus opens potential marketing angles around skin changes associated with hormonal transitions — but those angles must be carefully constructed to avoid drug claims about treating menopause as a condition.

---

Recent Clinical Research (2024–2026): What the Science Is Building

While this guide focuses primarily on regulatory science rather than clinical outcomes, it is important to situate that regulatory discussion within the broader scientific context. The adaptogen research landscape has continued to develop through 2024 and into 2026, with several notable publications and trials relevant to both the scientific and regulatory conversation.

2026: Mushroom Adaptogen Blend for Stress

A 2026 randomized, double-blind, placebo-controlled trial enrolled 50 adults with moderate-to-severe stress to evaluate an adaptogenic mushroom blend over 12 weeks. The trial design — with randomization, blinding, placebo control, and a validated stress population — represents the methodological gold standard for dietary supplement research. While the complete outcome statistics from this study's indexed excerpt were not fully available at the time of this writing, the trial design itself is noteworthy: it demonstrates that adaptogen researchers are increasingly applying the rigorous RCT framework that both the FDA and the FTC expect to see as the basis for substantiated claims.

For regulatory purposes, this kind of trial — even preliminary — contributes to the evidence base that would support structure/function claims for mushroom adaptogen products related to stress support.

2026: 13-Adaptogen Topical Serum Study

As detailed in the cosmetic adaptogens section above, the 2026 multicenter 16-week study of a 13-adaptogen topical serum produced statistically significant improvements across eight different skin outcome measures in a menopausal and postmenopausal population. The p < 0.0001 significance level across multiple endpoints is particularly impressive and reflects a well-powered, carefully designed clinical investigation.

2024: FDA Guidance on Complementary and Alternative Medicine Products

The FDA's 2024 guidance page on complementary and alternative medicine products is itself a relevant data point in this review. The guidance reaffirms the use-based classification framework and explicitly addresses botanicals and functional foods, confirming that their regulatory category is determined by intended use rather than by what the ingredient is. This guidance is consistent with longstanding FDA interpretation but provides a current, citable restatement of the agency's position.

Evidence Limitations

It is worth being transparent about what current research does and does not establish:

• Emerging clinical research on adaptogens is promising but fragmented. Studies vary widely in populations, dosages, outcome measures, and follow-up periods.
• No indexed 2024–2026 clinical results establish FDA recognition of adaptogens as a distinct class.
• No adaptogen product category has received FDA approval based on clinical trial evidence.
• The KSM-66 GRAS determination and similar GRAS notifications are safety determinations, not efficacy approvals.
• The regulatory framework has not changed in response to recent clinical research — the rules remain the same regardless of how good the science gets, unless Congress or the FDA takes formal action.

---

Are Adaptogens Legal? The Adaptogen Legal Framework Summarized

At this point in the article, the question "are adaptogens legal?" can be answered with precision and nuance.

The Short Answer

Yes — adaptogens are legal in the United States when they are:

• Sold as dietary supplements with structure/function claims.
• Made from ingredients with pre-1994 marketing history (or with an appropriate NDI notification).
• Free of drug claims.
• Labeled accurately and not misbranded.
• Manufactured under Good Manufacturing Practices (GMPs) as required by 21 CFR Part 111.

The Nuanced Answer

Adaptogen legal status is not a binary yes/no — it is a complex, use-dependent determination that changes based on:

1. What ingredient is being used: Most traditional adaptogens (ashwagandha, ginseng, rhodiola, eleuthero, schisandra, holy basil, tulsi, reishi) are widely considered to have pre-DSHEA marketing histories that support their use without NDI notifications. Novel extracts or isolated compounds may require NDI submissions.

1. What claims are being made: Legal structure/function claims are available. Disease claims make a product an unapproved drug — which is illegal.

1. What format the product takes: Adaptogen capsules follow dietary supplement rules. Adaptogen cosmetics follow cosmetic rules (now including MoCRA). Adaptogen-infused foods follow food rules, including GRAS requirements.

1. Who is manufacturing the product: Even a legal adaptogen product can be illegally sold if the manufacturer does not comply with GMP requirements, labeling rules, and applicable registration/listing obligations.

1. What jurisdiction matters: This article focuses on US federal law. State laws may impose additional requirements. International markets (EU, Canada, Australia) have substantially different regulatory frameworks, and an adaptogen legal in the US may not be legal — or may require different classification and labeling — in other jurisdictions.

The word "adaptogen" itself can appear on a supplement label without automatically requiring additional regulatory justification — it is a generic, non-specific term that does not inherently constitute a disease claim. However, the context in which it appears, and the other claims made alongside it, determine whether the overall label crosses into drug-claim territory.

---

---

Third-Party Certifications: USP, NSF, and What They Actually Mean

Consumers evaluating adaptogen supplement quality frequently encounter third-party certification seals on product labels: USP Verified, NSF Certified for Sport, Informed Sport, ConsumerLab.com Approved, and others. Understanding what these certifications do and do not represent is essential for making informed purchasing decisions.

What Third-Party Certifications Test

Third-party supplement certifications typically evaluate one or more of the following:

• Identity: Does the product actually contain the ingredients it claims to contain?
• Potency: Are the ingredients present at the levels stated on the label?
• Purity: Is the product free from specified contaminants (heavy metals, pesticides, microbial contamination)?
• Manufacturing standards: Are GMPs being followed?

For adaptogen products, these certifications are particularly valuable because the herbal supplement market has historically been plagued by adulteration and identity fraud. Studies have found that some adaptogen products contain little or none of the advertised ingredient, while others contain undisclosed botanical materials that may have safety implications.

USP Verification

The U.S. Pharmacopeia (USP) Verified mark indicates that a product has met USP's standards for identity, potency, quality, and purity, and that it was manufactured under GMPs. USP verification is voluntary and requires annual re-testing.

NSF Certification

NSF International offers several supplement certification programs, including NSF Certified for Sport (which additionally screens for substances banned in athletic competition). NSF certification indicates that a product has been tested for label claim accuracy and contamination.

What These Certifications Do NOT Indicate

Critically, neither USP, NSF, nor any other third-party supplement certification indicates:

• FDA approval of the product.
• Proven efficacy of the product.
• That the product's health claims are substantiated.
• That the product is safe for all individuals under all conditions.

Third-party certifications address product quality and label accuracy. They are valuable and meaningful quality indicators, but they operate entirely outside the FDA regulatory framework and should not be confused with government approval.

How Consumers Can Verify Product Quality

For adaptogen supplements specifically, quality verification steps include:

1. Look for USP, NSF, or Informed Sport certification seals on labels.
2. Check ConsumerLab.com's independent testing database for specific product reports.
3. Verify that the product lists the specific extract form (e.g., KSM-66, Sensoril, Shoden for ashwagandha) and standardization percentages.
4. Confirm GMP compliance claims and, where possible, verify FDA facility registration.
5. Research whether the specific extract has been the subject of clinical trials.

---

Safety, Drug Interactions, and Consumer Due Diligence

No regulatory science guide would be complete without addressing the safety dimension of adaptogen use, because the regulatory framework — which does not require premarket safety review for most adaptogen supplements — places significant responsibility on consumers and clinicians to exercise independent judgment.

General Safety Profile

Most traditional adaptogens have favorable safety profiles in healthy adults at typical supplemental doses. The historical use of herbs like ashwagandha, ginseng, and rhodiola across centuries and multiple cultures provides a baseline of empirical safety data that, while not equivalent to clinical trial evidence, is not without value.

However, "generally safe for healthy adults at normal doses" is not the same as "safe for everyone in all circumstances." Specific safety considerations include:

Ashwagandha Safety Considerations

• Hepatotoxicity risk: Case reports of liver injury associated with ashwagandha supplements have been published, leading to precautionary warnings in several European countries. The risk appears to be idiosyncratic and rare but is not negligible. Pre-existing liver conditions are a contraindication.
• Thyroid effects: Ashwagandha may increase thyroid hormone levels, which creates risk for individuals with hyperthyroidism or those taking thyroid medications.
• Pregnancy: Ashwagandha is contraindicated during pregnancy due to potential uterotonic effects.
• Drug interactions: Potential interactions with immunosuppressants, thyroid medications, sedatives, and anticoagulants.

Rhodiola Safety Considerations

• Generally well-tolerated, but may cause stimulant-like effects (agitation, insomnia) at high doses.
• May interact with antidepressants and MAO inhibitors.

Ginseng Safety Considerations

• "Ginseng abuse syndrome" at very high doses.
• Potential interactions with warfarin, diabetes medications, and stimulants.
• Panax ginseng may have estrogenic activity — relevant for hormone-sensitive conditions.

Medicinal Mushroom Safety Considerations

• Reishi may increase bleeding risk; caution with anticoagulants.
• Some individuals experience gastrointestinal side effects.
• Rare but documented allergic reactions.

The Clinician Conversation

Given that supplement regulation does not mandate clinical interaction screening or safety disclosures beyond basic label requirements, consumers are strongly encouraged to discuss adaptogen use with a qualified healthcare provider before beginning supplementation, particularly if they:

• Are taking prescription medications.
• Have existing medical conditions.
• Are pregnant or breastfeeding.
• Are scheduled for surgery.
• Are under 18 or over 65.

The absence of FDA premarket review means that the safety evaluation defaults largely to the individual and their healthcare provider.

---

Key Takeaways for Industry Professionals and Consumers

After thousands of words of regulatory nuance, here is a summary of the most important takeaways from this guide:

For Consumers

1. "FDA approved" and "dietary supplement" are mutually exclusive for most adaptogen products. Supplements sold under DSHEA do not receive premarket FDA approval. The disclaimer on the label is legally required and factually accurate.

1. The FDA does not recognize "adaptogen" as a regulatory category. The term can appear on labels, but it triggers no special regulatory review.

1. Third-party certifications (USP, NSF) indicate quality testing — not FDA approval or proven efficacy.

1. Adaptogens can interact with medications and are not safe for everyone. Discuss supplement use with your healthcare provider.

1. If a product claims to treat, cure, or prevent a disease, it is either an approved drug (rare) or an unapproved drug (concerning). Avoid products that make disease claims — they may not only be illegal but potentially unsafe.

For Industry Professionals and Formulators

1. Classification is use-dependent. The same botanical becomes a different regulatory product based on format and claims. Know which lane your product occupies before you market it.

1. NDI status requires careful analysis. Do not assume that a traditional botanical's pre-1994 history covers your novel extract or highly standardized concentration.

1. KSM-66 GRAS is a model — not a blanket cover. GRAS determinations are ingredient-specific. Other ashwagandha extracts are not automatically covered by KSM-66's GRAS status.

1. Claim substantiation is a real obligation, not a formality. Both FDA and FTC expect competent and reliable scientific evidence. Well-designed RCTs are the gold standard.

1. MoCRA changes the cosmetic adaptogen landscape. Facility registration and product listing are now required for cosmetic products. Safety substantiation obligations are real.

1. Monitor international safety signals. European regulatory actions on ashwagandha hepatotoxicity may foreshadow increased FDA post-market scrutiny.

---

Frequently Asked Questions

Is "adaptogen" an FDA-recognized category?

No. The FDA does not recognize "adaptogen" as a formal regulatory category. There is no FDA definition of an adaptogen, no special approval pathway for adaptogen products, and no regulatory standard that applies specifically to adaptogens as a class. Products marketed as adaptogens are classified based on their intended use, format, and claims — most commonly as dietary supplements.

Does the FDA approve adaptogen supplements before they are sold?

No. Under DSHEA, dietary supplements do not require FDA premarket approval. Manufacturers are responsible for ensuring safety and accurate labeling, and the FDA exercises oversight primarily through post-market actions such as inspections, warning letters, and recalls.

Are adaptogens classified as drugs, dietary supplements, foods, or cosmetics?

All of the above — it depends on the product. Adaptogen capsules sold with structure/function claims are dietary supplements. Adaptogen-fortified beverages may be foods. Adaptogen skincare products are cosmetics. Any adaptogen product making disease treatment claims is legally a drug (and typically an unapproved one).

What makes an adaptogen a dietary supplement rather than an unapproved drug?

The claims made about it. A dietary supplement can make structure/function claims (e.g., "supports healthy stress response") but cannot make disease claims (e.g., "treats anxiety disorder"). If disease claims are made, the product is a drug under the FD&C Act, regardless of what it is physically made of.

Can a company claim that an adaptogen treats anxiety, fatigue, hormonal imbalance, or cortisol problems?

No — not in the context of treating diseases or medical conditions. These topics can be addressed through carefully crafted structure/function claims (e.g., "helps support a calm and relaxed state" or "supports healthy energy levels"), but claims that explicitly reference treating diagnosed conditions are drug claims that require FDA drug approval.

What is the difference between an FDA disclaimer and FDA approval?

The required disclaimer — "These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease" — is a mandatory disclosure that the FDA has not evaluated the specific claim. It is the opposite of FDA approval. FDA approval would mean the FDA reviewed evidence and found the product effective for a specific use. The disclaimer means no such review occurred.

Do adaptogens require a New Dietary Ingredient notification?

It depends. Ingredients not marketed in the US as dietary supplements before October 15, 1994 require an NDI notification. Many traditional adaptogens have pre-1994 histories and may not require notifications for their standard forms. Novel extracts, unusual concentrations, or significantly modified forms may require NDI notifications even for traditional botanicals.

How does the FDA determine whether an ingredient is "new"?

The FDA considers the marketing history of the ingredient, its specific form and preparation, and whether the substance was sold as a dietary supplement in the United States before October 15, 1994. Changes in extraction methods, significant increases in concentration, or new delivery forms may create a new dietary ingredient even for botanicals with historical use.

Are ashwagandha, rhodiola, ginseng, and medicinal mushrooms regulated differently from each other?

At the categorical level, no — all are subject to the same dietary supplement regulatory framework under DSHEA. Individual differences arise from ingredient-specific safety data, NDI status determinations, GRAS designations (like KSM-66 GRAS for ashwagandha), and the specific claims made about each product.

What evidence is required to support stress, sleep, energy, or cortisol claims?

"Competent and reliable scientific evidence" — the standard applied by both the FDA and the FTC. While the standard does not mandate a specific number of clinical trials, well-designed RCTs with validated outcome measures are the gold standard. The evidence must exist before the claim is made.

How can consumers verify adaptogen product quality?

Look for third-party certification seals (USP Verified, NSF Certified), verify the specific branded extract used (e.g., KSM-66, Sensoril), check ConsumerLab.com for independent product testing, confirm the manufacturer lists GMP compliance, and research whether the specific ingredient has been clinically studied.

Do USP, NSF, or other third-party certifications indicate FDA approval?

No. Third-party certifications evaluate quality characteristics (identity, potency, purity, manufacturing standards) but operate outside the FDA regulatory framework. They do not indicate FDA approval, proven efficacy, or safety for all individuals.

What safety issues and medication interactions should consumers consider?

Ashwagandha may affect thyroid function and liver health; rhodiola may cause stimulant-like effects; ginseng may interact with warfarin; reishi may affect bleeding time. Always discuss adaptogen supplementation with a healthcare provider, especially if taking prescription medications or managing existing medical conditions.

Can the word "adaptogen" appear on a supplement label without additional substantiation?

Yes — the term "adaptogen" alone does not constitute a claim requiring formal substantiation. However, any specific claims made alongside the term (about stress, energy, sleep, etc.) must be substantiated, and the overall context of the label must not create an implied disease claim.

---

---

Conclusion

The regulatory landscape for adaptogens in the United States is defined by a foundational absence: the FDA does not recognize "adaptogen" as a formal regulatory category, and no FDA adaptogen approval process exists. What exists instead is a sophisticated, use-dependent framework that routes adaptogen products into different legal categories based on what they claim to do and how they are presented to consumers.

For most of the American adaptogen market, that framework routes products through DSHEA's dietary supplement provisions — a system that enables rapid market access and places primary safety responsibility on manufacturers, while reserving FDA enforcement for post-market issues. For topical products, MoCRA's new cosmetic requirements are reshaping obligations around registration, listing, and safety documentation. For ingredients with food applications, GRAS determinations like KSM-66 GRAS provide a formal safety basis for use in conventional food products. And for any product that crosses into disease claims — whether through explicit labeling or implied marketing — the drug regulatory pathway applies, with all of the premarket approval requirements that pathway entails.

The adaptogen supplement regulation environment is simultaneously more permissive than many consumers assume (no premarket approval, no efficacy review) and more legally demanding than many manufacturers appreciate (robust claim substantiation requirements, GMP obligations, NDI analysis, dual FDA/FTC oversight of advertising).

For consumers, the most important literacy skill is understanding what the required disclaimer actually means: that the FDA has not reviewed the claim, not that the product is safe or effective. Third-party certifications, published clinical research on specific branded extracts, and consultation with qualified healthcare providers are the tools that fill the evidence gap that regulatory oversight leaves open.

For industry professionals, the path forward is the same as it has always been in responsible supplement manufacturing: rigorous ingredient sourcing, honest and substantiated claims, full regulatory compliance, and investment in the clinical research that gradually builds the evidence base the market needs and regulators increasingly expect.

Adaptogens have genuine scientific interest behind them. The regulatory framework does not validate them — but it also does not invalidate them. It simply places the burden of proof where DSHEA always placed it: on the manufacturers who make the claims and the consumers who choose to believe them.

---

This article is provided for educational and informational purposes only and does not constitute legal advice. Regulatory determinations depend on specific facts and circumstances. Consult qualified regulatory counsel before making product classification or labeling decisions.

---

Sources referenced in this article include FDA regulatory guidance documents, DSHEA statutory text, FTC dietary supplement advertising guidance, the Modernization of Cosmetics Regulation Act (MoCRA), published clinical research cited within the text, and FDA GRAS notification program records.